Recent Acquisition Affera was acquired by Medtronic for nearly $925 million in August 2022, highlighting its strategic importance and potential for integration into broader healthcare solutions, which offers expansion opportunities for related medical device providers.

Innovative Technology Specializing in systems for treating heart rhythm disorders, Affera develops advanced medical devices that are aligned with current trends in minimally invasive cardiac therapies, making it a prime target for vendors offering complementary cardiovascular equipment.

Growth & Funding With recent Series A funding of $8 million and a revenue range of $1 million to $10 million, the company is positioned for growth and open to partnerships that can accelerate product development and market penetration.

Market & Competitors Operating within a competitive landscape alongside firms like Abbott and Boston Scientific, Affera's niche focus on heart rhythm disorder treatment represents an opportunity to connect with medical suppliers targeting the electrophysiology segment.

Operational Expansion Relocating offices to Watertown, NY, indicates operational scaling and potentially new market access points, providing sales teams with localized opportunities to engage with their expanding presence and related healthcare providers.